Methods and compositions for treating polycystic ovary syndrome
View Patent ↗The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1) to subjects suffering therefrom.
1. A method of treating a subject suffering from polycystic ovary syndrome (PCOS) comprising the step of administering to a subject suffering from PCOS an amount of a GLP-1 molecule effective to treat at least one symptom of PCOS.
2. The method according to claim 1 , wherein the symptom is selected from the group consisting of insulin resistance, hyperinsulinemia, type-2 diabetes, obesity, hypertension, hyperlipidemia, anovulation or irregular ovulation, infertility, hyperandrogenism, hirsutism, alopecia, acne, enlarged multifollicular ovaries; abnormal uterine bleeding, and spontaneous abortion.
3. A method of reducing insulin resistance in a subject suffering from PCOS comprising the step of administering to a subject suffering from PCOS an amount of a GLP-1 molecule effective to reduce insulin resistance, wherein said insulin resistance is a symptom of PCOS.
4. A method of preventing the onset of type-2 diabetes in a subject suffering from PCOS comprising the step of administering to a subject suffering from PCOS an amount of a GLP-1 molecule effective to prevent the onset of type-2 diabetes, wherein said type-2 diabetes is a symptom of PCOS.
5. A method of restoring regular menses in a subject suffering from PCOS comprising the step of administering to a subject suffering from PCOS an amount of a GLP-1 molecule effective to restore regular menses, wherein irregular menses is a symptom of PCOS.
6. A method of restoring regular ovulation in a subject suffering from PCOS comprising the step of administering to a subject suffering from PCOS an amount of a GLP-1 molecule effective to restore regular ovulation, wherein anovulation or irregular ovulation is a symptom of PCOS.
7. A method of restoring fertility in a subject suffering from PCOS comprising the step of administering to a subject suffering from PCOS an amount of a GLP-1 molecule effective to restore fertility, wherein the infertility is a symptom of PCOS.
8. A method for preventing spontaneous abortion in a subject suffering from PCOS comprising the step of administering to a subject suffering from PCOS an amount of a GLP-1 molecule effective to prevent spontaneous abortion, wherein said spontaneous abortion is a symptom of PCOS.
9. The method according to any one of claims 1 to 8 , wherein the subject is human.
10. The method according to any one of claims 1 to 8 , wherein the GLP-1 molecule is selected from the group consisting of GLP-1(7–36)NH 2 , GLP-1(7–37), and exendin-4.
11. The method according to any one of claims 1 to 8 , wherein the GLP-1 molecule is selected from the group consisting of GLP-1(7–36)NH 2 and GLP-1(9–36)NH 2 .
12. The method according to any one of claims 1 to 8 wherein the GLP-1 is coadministered by an infusion pump or by subcutaneous injection of a slow release formulation.
13. The method according to any one of claims 1 to 8 wherein the GLP-1 is coadministered with an agent selected from the group consisting of an ovulation inducing drug, an anti-androgenic drug, an insulin-sensitizing agent and glucose.
14. The method according to claim 13 wherein the ovulation inducing drug is selected from the group consisting of clomiphene, follistim, and Gonal-F.
15. The method according to claim 13 wherein the anti-androgenic drug is selected from the group consisting of a birth control pill, spironolactone, flutamide, and finasteride.
16. The method according to claim 13 wherein the insulin-sensitizing agent is selected from the group consisting of metformin, D-Chiro-inositol, diazoxide, and PPAR inhibitor.
17. The method according to claim 13 , wherein the glucose is administered intravenously.
18. The method according to claim 13 , wherein the GLP-1 and the agent are administered either sequentially or concurrently.
19. The method of claim 16 , wherein said PPAR inhibitor is triglitazone, rosiglitazone, or pioglitazone.
20. The method according to any one of claims 1 to 8 , wherein the GLP-1 molecule is exendin-4.